Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system (Q36872293)

16 August 2017

1 reference

title

Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system (English)

1 reference

16 August 2017

1 reference

0 references

Karl-Erik Andersson

1

1 reference

16 August 2017

Christian Gratzke

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

16 August 2017

published in

Nature Reviews Urology

1 reference

16 August 2017

volume

4

1 reference

16 August 2017

issue

7

1 reference

16 August 2017

page(s)

368-378

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpuro0836

16 August 2017

exact match

0 references

cites work

Prejunctional facilitatory α1‐adrenoceptors in the rat urinary bladder

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FNCPURO0836

21 January 2018

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

The alpha1L-adrenoceptor subtype in the lower urinary tract: a comparison of human urethra and prostate.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

Quantitative autoradiography of alpha 1 adrenoceptors with [3H]tamsulosin in human hypertrophied prostate using computerized image analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

Alpha 1A-adrenoceptor-mediated contractile responses of the human vas deferens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

Micturition in conscious rats with and without bladder outlet obstruction: role of spinal alpha 1-adrenoceptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Storage and voiding symptoms: pathophysiologic aspects

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

The effect of terazosin on functional bladder outlet obstruction in women: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Increased contractile response to phenylephrine in detrusor of patients with bladder outlet obstruction: effect of the alpha1A and alpha1D-adrenergic receptor antagonist tamsulosin

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Effect of tamsulosin on spontaneous bladder contraction in conscious rats with bladder outlet obstruction: comparison with effect on intraurethral pressure

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Effect of doxazosin on rat urinary bladder function after partial outlet obstruction

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Smooth muscle and parasympathetic nerve terminals in the rat urinary bladder have different subtypes of alpha(1) adrenoceptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

The influence of alpha1-adrenoreceptors on neuropeptide release from primary sensory neurons of the lower urinary tract

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Mechanisms of disease: involvement of the urothelium in bladder dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Activation of alpha1D adrenergic receptors in the rat urothelium facilitates the micturition reflex

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

The Effects of Epidural Anesthesia on the Urethral Closure Pressure Profile in Patients with Prostatic Enlargement

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

alpha1-adrenoceptors in urethral function

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Quantification and distribution of alpha1-adrenoceptor subtype mRNAs in human proximal urethra

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Evidence for predominant mediation of alpha1-adrenoceptor in the tonus of entire urethra of women

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Human cloned alpha1A-adrenoceptor isoforms display alpha1L-adrenoceptor pharmacology in functional studies

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Binding and functional properties of alpha1 adrenoceptors in different regions of the human prostate

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Multidirectional contraction of human hypertrophied prostate

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Identification of alpha-1L and alpha-1A adrenoceptors in human prostate by tissue segment binding

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Apoptotic activity of doxazosin on prostate stroma in vitro is mediated through an autocrine expression of TGF-beta1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Influence of the alpha1-adrenergic antagonist, doxazosin, on noradrenaline-induced modulation of cytoskeletal proteins in cultured hyperplastic prostatic stromal cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Modulation of the differentiation status of cultured prostatic smooth muscle cells by an alpha1-adrenergic receptor antagonist

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Ejaculatory disorders and lower urinary tract symptoms

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Functional characterization of alpha1-adrenoceptor subtypes in longitudinal and circular muscle of human vas deferens

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Evaluation of tamsulosin and alfuzosin activity in the rat vas deferens: relevance to ejaculation delays

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

A comparison of the effects of tamsulosin and alfuzosin on neurally evoked increases in bladder neck and seminal vesicle pressure in rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Comparison between tamsulosin and alfuzosin on the expulsion phase of ejaculation in rats.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Distribution of alpha1A adrenergic receptor mRNA in the rat brain visualized by in situ hybridization.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Distribution of alpha 1a-, alpha 1b- and alpha 1d-adrenergic receptor mRNA in the rat brain and spinal cord

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Central nervous system control of the lower urinary tract: new pharmacological approaches to stress urinary incontinence in women

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Role of spinal α1-adrenergic mechanisms in the control of lower urinary tract in the rat

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Role of spinal alpha1-adrenoceptor subtypes in the bladder reflex in anesthetized rats

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Improvement of bladder storage function by alpha1-blocker depends on the suppression of C-fiber afferent activity in rats.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Function of the lower urinary tract in mice lacking alpha1d-adrenoceptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Transplantation of neuronal and glial restricted precursors into contused spinal cord improves bladder and motor functions, decreases thermal hypersensitivity, and modifies intraspinal circuitry.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL).

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Tolerability of alpha-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Alpha1-blocker therapy for lower urinary tract symptoms suggestive of benign prostatic obstruction: what are the relevant differences in randomised controlled trials?

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Comparison of doxazosin GITS and standard doxazosin in the treatment of high blood pressure.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Oral phentolamine as treatment for erectile dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Impact of treatment of BPH on sexuality

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Effects of Acute Treatment With Tamsulosin Versus Alfuzosin on Ejaculatory Function in Normal Volunteers

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Effects of alpha(1)-adrenoceptor antagonists on male sexual function

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Recovery of abnormal ejaculation by intermittent tamsulosin treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Intraoperative floppy iris syndrome associated with tamsulosin

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonist

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Intraoperative 'floppy iris' syndrome and its relationship to tamsulosin: a urologist's guide

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

alpha(1)-Adrenergic receptor antagonists and the iris: new mechanistic insights into floppy iris syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0836

7 January 2021

Identifiers

DOI

10.1038/NCPURO0836

1 reference

Dimensions Publication ID

16 August 2017

1049718270

0 references

1 reference